Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PRCT
Strong SellSinkerPROCEPT BioRobotics Corporation · Healthcare · United States · $1.2B · Avg Vol: $30M/d
COMPANY DESCRIPTION
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company focused on developing transformative solutions in urology, primarily for the treatment of benign prostatic hyperplasia (BPH). The company's competitive moat is anchored by its proprietary AquaBeam Robotic System, which delivers Aquablation therapy—the first FDA-cleared, image-guided, heat-free waterjet tissue ablation technology. Backed by robust clinical data demonstrating superior safety and efficacy profiles compared to traditional surgeries, PROCEPT is rapidly establishing Aquablation as the new standard of care for BPH.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 75.0M | 136.2M | 224.5M | 308.1M | 60.1% | 337.3M | 395.4M | 476.9M | 24.4% |
| EPS | -1.96 | -2.24 | -1.75 | -1.72 | — | -1.95 | -1.68 | -1.15 | — |
| Shares | 44.8M | 50.8M | 54.7M | 56.3M | +25.6% | 56.9M | — | — | — |
| Debt | 77.3M | 79.2M | 80.3M | 78.5M | 0.5% | 77.5M | — | — | — |
| Equity | 197.1M | 280.8M | 402.2M | 365.9M | 22.9% | — | — | — | — |
| Op CF | -80.4M | -108.0M | -99.2M | -49.0M | — | -74.3M | — | — | — |
| Inv CF | -2.7M | -25.2M | -4.4M | -9.4M | — | — | — | — | — |
| Fin CF | 3.6M | 167.8M | 180.1M | 11.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PRCT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PRCT | PROCEPT BioRobotics Corporation(you) | $1.2B | 15 | Strong Sell |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.1B | 28 | Sell |
| ATEC | Alphatec Holdings, Inc. | $1.5B | 27 | Sell |
| ALMR | Alamar Biosciences, Inc. | $2.1B | 20 | Sell |
| CBLL | CeriBell, Inc. | $911M | 27 | Sell |
| QDEL | QuidelOrtho Corporation | $1.0B | 29 | Sell |
| BBNX | Beta Bionics, Inc. | $887M | 27 | Sell |
| ESTA | Establishment Labs Holdings Inc. | $2.1B | 23 | Sell |
| PACB | Pacific Biosciences of California, Inc. | $435M | 16 | Strong Sell |
| TNDM | Tandem Diabetes Care, Inc. | $1.5B | 31 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%